Dwindling supplies of Ozempic are fuelling an “exploding” black market for the drug across Australia, as the medical industry is forced to assess which patients need the popular medication the most.
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
UBS's Jo Walton reiterated the Swiss bank's buy recommendation on Novo Nordisk stock at a price target of 750 Danish kroner ($110) per share. It wasn't immediately apparent why the analyst ...
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Novo Nordisk received a boost from a bullish analyst note. The company also continues to be the pacesetter in the limited market for weight-loss drugs. That gravity-defying boost was due in no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results